Roivant Sciences Ltd (ROIV)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 4 |
| Ownership rank: | 207 |
| % of all portfolios: | 0.042% |
| Hold Price * : | $35.39 |
| Total insider Buys/Sells last 6 months: |
| Transactions | Total |
| Buys |
0 |
$0 |
| Sells |
44 |
$277,096,406 |
|
Portfolio Manager |
% of portfolio |
Recent activity |
Shares |
Value |
| ≡ |
David Einhorn - Greenlight Capital |
1.95 |
|
2,152,669 |
76,183,000 |
| ≡ |
Lee Ainslie - Maverick Capital |
0.90 |
Add 73.89% |
2,829,024 |
100,119,000 |
| ≡ |
Viking Global Investors |
0.63 |
Reduce 5.73% |
6,271,467 |
221,947,000 |
| ≡ |
Polen Capital Management |
0.00 |
Buy |
8,659 |
306,000 |
Open Market Insider Buys
| Date Filed |
Reporting Name |
Relationship |
Trans. Date |
Shares |
Price $ |
Total Value $ |
| 18 Sep 2025 |
GLINE MATTHEW |
CEO |
18 Sep 2025 |
3,315 |
15.07 |
49,957 |
| 14 Nov 2022 |
DEXCEL PHARMA TECHNOLOGIES LTD. |
10% |
10 Nov 2022 |
4,000,000 |
5.00 |
20,000,000 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.
P = Preferred Stock